Celltrion Healthcare Co Ltd
KOSDAQ:091990
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
N/A
N/A
|
| Price Target |
|
We'll email you a reminder when the closing price reaches KRW.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Celltrion Healthcare Co Ltd
Celltrion Healthcare Co Ltd
Celltrion Healthcare Co Ltd has carved a distinctive niche in the competitive biotechnology landscape by capitalizing on its expertise in biosimilars, which are biopharmaceutical drugs almost identical to original products. The company's origins trace back to a broader vision of democratizing healthcare, striving to make biologic treatments more accessible and affordable worldwide. With its roots in South Korea, Celltrion Healthcare, a subsidiary of Celltrion Inc., has harnessed cutting-edge technology to replicate complex biological drugs. These drugs, usually utilized for chronic conditions such as autoimmune diseases and cancer, are pivotal in offering alternatives to high-cost branded biologics. By focusing on biosimilars, Celltrion addresses both a global healthcare cost crisis and a burgeoning demand for effective therapies as aging populations grow.
The business model revolves around developing, manufacturing, and distributing these biosimilars. Celltrion Healthcare primarily benefits from the lower production costs compared to innovator biologics and the subsequent market penetration achieved through competitive pricing. They have established an extensive global distribution network, which enhances their reach. Collaborations with various international partners bolster their presence in strategic markets, allowing comprehensive coverage across multiple continents. Revenue is generated from licensing agreements, direct sales, and strategic partnerships, ensuring a diversified income stream. In parallel, the company's vigorous pipeline of new products promises sustained growth, aimed at expanding their therapeutic portfolio while leveraging their expertise to outpace competitors in this burgeoning field.
Celltrion Healthcare Co Ltd has carved a distinctive niche in the competitive biotechnology landscape by capitalizing on its expertise in biosimilars, which are biopharmaceutical drugs almost identical to original products. The company's origins trace back to a broader vision of democratizing healthcare, striving to make biologic treatments more accessible and affordable worldwide. With its roots in South Korea, Celltrion Healthcare, a subsidiary of Celltrion Inc., has harnessed cutting-edge technology to replicate complex biological drugs. These drugs, usually utilized for chronic conditions such as autoimmune diseases and cancer, are pivotal in offering alternatives to high-cost branded biologics. By focusing on biosimilars, Celltrion addresses both a global healthcare cost crisis and a burgeoning demand for effective therapies as aging populations grow.
The business model revolves around developing, manufacturing, and distributing these biosimilars. Celltrion Healthcare primarily benefits from the lower production costs compared to innovator biologics and the subsequent market penetration achieved through competitive pricing. They have established an extensive global distribution network, which enhances their reach. Collaborations with various international partners bolster their presence in strategic markets, allowing comprehensive coverage across multiple continents. Revenue is generated from licensing agreements, direct sales, and strategic partnerships, ensuring a diversified income stream. In parallel, the company's vigorous pipeline of new products promises sustained growth, aimed at expanding their therapeutic portfolio while leveraging their expertise to outpace competitors in this burgeoning field.
Earnings Calls
You don't have any saved screeners yet
